IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Henriksen et al.

Attorney Docket No.: 5683.210-US

Confirmation No: 5300

PAGE 13/16

PATENT

Serial No.: 10/618,477

Group Art Unit: 1651

Filed: July 11, 2003

Examiner: D. Naff

For: Solid Phytase Compositions

TERMINAL DISCLAIMER TO OBVIATE A DOUBLE PATENTING REJECTION OVER A PRIOR PATENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir.

I am an attorney or agent of record for the instant application.

Novozymes A/S, the owner of the entire interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. 154 to 156 and 173, as presently shortened by any terminal disclaimer, of prior U.S. Patent No. 6,610,519. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and the prior patent are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend beyond the expiration date of the full statutory term as defined in 35 U.S.C. 154 to 156 and 173 of the prior patent, as presently shortened by any terminal disclaimer, in the event that it later: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims cancelled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as shortened by any terminal disclaimer.

09/22/2006 EFLORES 00000003 501701 10618477

01 FC:1814 130.00 DA

Please charge the required fee, estimated to be \$110.00, to Novozymes North America, Inc. Deposit Account No. 50-1701. A duplicate of this sheet is enclosed.

Respectfully submitted,

Date: September 21, 2006

Elias J. Lambiris, Reg. No. 33,728 Novozymes North America, Inc. 500 Fifth Avenue, Suite 1600

New York, NY 10110 (212) 840-0097